{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:10:54Z","timestamp":1778721054291,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:04:59Z","timestamp":1773407099000},"page":"193-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-Evaluating the Role of Locoregional Therapy in Metastatic Prostate Cancer: A Review of Current Evidence and Evolving Clinical Approaches"],"prefix":"10.1016","volume":"53","author":[{"given":"Ismail","family":"Ajjawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preston C.","family":"Sprenkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Renzulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ucl.2017.07.008","article-title":"Newly diagnosed metastatic prostate cancer: has the paradigm changed?","volume":"44","author":"Damodaran","year":"2017","journal-title":"Urol Clin North Am"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000519861","article-title":"Metastatic prostate cancer: treatment options","volume":"100","author":"Achard","year":"2022","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12904-018-0381-6","article-title":"Quality of life in men with metastatic prostate cancer in their final years before death - a retrospective analysis of prospective data","volume":"17","author":"Holm","year":"2018","journal-title":"BMC Palliat Care"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1188\/20.CJON.369-378","article-title":"Metastatic prostate cancer: an update on treatments and a review of patient symptom management","volume":"24","author":"Drudge-Coates","year":"2020","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.002_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1055\/s-0043-100492","article-title":"Beeinflussung der Lebensqualit\u00e4t beim metastasierten kastrationsresistenten Prostatakarzinom \u2013 eine \u00dcbersicht [Review on quality of life in CRPC patients]","volume":"48","author":"Miller","year":"2017","journal-title":"Aktuelle Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2017.03.020","article-title":"Local therapy improves survival in metastatic prostate cancer","volume":"72","author":"Leyh-Bannurah","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2016.04.031","article-title":"The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis","volume":"72","author":"L\u00f6ppenberg","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.002_bib8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pros.23294","article-title":"Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer","volume":"77","author":"Parikh","year":"2017","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.002_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/SPC.0000000000000218","article-title":"Rationale for local treatment in the management of metastatic prostate cancer","volume":"10","author":"Gandaglia","year":"2016","journal-title":"Curr Opin Support Palliat Care"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.002_bib10","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/j.clgc.2017.04.013","article-title":"Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: a Single Institution Retrospective Analysis From the Royal Marsden Hospital","volume":"15","author":"Bianchini","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.002_bib11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MOU.0000000000000444","article-title":"Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?","volume":"27","author":"Blanchard","year":"2017","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ucl.2026.02.002_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2017.12.012","article-title":"Loco-regional treatment for castration-resistant prostate cancer: is there any rationale? A critical review from the AFU-GETUG","volume":"122","author":"Beauval","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.002_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00345-015-1607-3","article-title":"Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy","volume":"34","author":"Kadono","year":"2016","journal-title":"World J Urol"},{"issue":"14","key":"10.1016\/j.ucl.2026.02.002_bib14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/pros.24767","article-title":"Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED\/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer","volume":"84","author":"Wenzel","year":"2024","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib15","doi-asserted-by":"crossref","first-page":"158.e13","DOI":"10.1016\/j.urolonc.2017.12.009","article-title":"Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial","volume":"36","author":"Buelens","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2026.02.002_bib16","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7804932","article-title":"Prognostic value of the LATITUDE and CHAARTED risk criteria for predicting the survival of men with bone metastatic hormone-na\u00efve prostate cancer treated with combined androgen blockade therapy: real-world data from a Japanese multi-institutional study","volume":"2020","author":"Kawahara","year":"2020","journal-title":"BioMed Res Int"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.prnil.2022.01.001","article-title":"Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer","volume":"10","author":"Chikamatsu","year":"2022","journal-title":"Prostate Int"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.002_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-based [(18)F]DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol Imag Biol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.002_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.euf.2019.05.005","article-title":"Can Ga-68 PSMA PET\/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?","volume":"6","author":"Esen","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2214\/AJR.20.24711","article-title":"Role of 18F-Fluciclovine and Prostate-Sprostate-smbrane Amtigen PEa\/CT in Guiding Magagementmof Oligometasoatic Prostate Cpncer: AJc Expert Panel Narrative neview","volume":"216","author":"Savir-Baruch","year":"2021","journal-title":"AJr Am J Roentgenol"},{"issue":"14","key":"10.1016\/j.ucl.2026.02.002_bib22","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.3390\/cancers14143302","article-title":"Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer","volume":"14","author":"Galgano","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.ucl.2026.02.002_bib23","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.3390\/cancers14246194","article-title":"Management of patients with recurrent and metachronous oligometastatic prostate cancer in the era of PSMA PET","volume":"14","author":"Sabbagh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.002_bib24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1148\/rg.2020200058","article-title":"Prostate-specific membrane antigen PET: therapy response assessment in metastatic prostate cancer","volume":"40","author":"Barbosa","year":"2020","journal-title":"Radiographics"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.semnuclmed.2019.02.005","article-title":"Molecular imaging of recurrent and metastatic prostate cancer","volume":"49","author":"Ware","year":"2019","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.09.003","article-title":"European Association of nuclear medicine focus 5: consensus on molecular imaging and theranostics in prostate cancer","volume":"85","author":"Oprea-Lager","year":"2024","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.002_bib27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MOU.0000000000000449","article-title":"Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology","volume":"27","author":"Joice","year":"2017","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant human tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J Surg"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.002_bib30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"10276","key":"10.1016\/j.ucl.2026.02.002_bib31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.002_bib32","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-Radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib33","first-page":"62","article-title":"Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 Radioligand Therapy","volume":"61","author":"Sathekge","year":"2020","journal-title":"J NucltMed"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.002_bib34","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.002_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 Prior to Radicap Prostatrctomy ip Men with High-rmsk Localhsed Prostlte Cancerp(LuTectomy): A Single-centrea single-arm, Phase 1\/2 Study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.002_bib36","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: phase I trial of \u02c6177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.02.002_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231179309","article-title":"Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Kostos","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.002_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.002_bib39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"10467","key":"10.1016\/j.ucl.2026.02.002_bib40","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.002_bib41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/MOU.0000000000000675","article-title":"Prostate radiotherapy in newly diagnosed metastatic prostate cancer","volume":"29","author":"Ali","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"24","key":"10.1016\/j.ucl.2026.02.002_bib42","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","article-title":"Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer","volume":"34","author":"Rusthoven","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.002_bib43","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.juro.2015.02.084","article-title":"Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis","volume":"194","author":"Satkunasivam","year":"2015","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.002_bib44","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ijrobp.2019.08.008","article-title":"Radiation therapy in the definitive management of oligometastatic prostate cancer: the Johns Hopkins experience","volume":"105","author":"Deek","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147191","article-title":"Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?","volume":"11","author":"Cho","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib46","first-page":"6373","article-title":"Late toxicity rates following definitive radiotherapy for prostate cancer","volume":"19","author":"Ohri","year":"2012","journal-title":"Can J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.002_bib47","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.002_bib48","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20171379","article-title":"The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis","volume":"38","author":"Wang","year":"2018","journal-title":"Biosci Rep"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.urolonc.2017.01.001","article-title":"Role of radical prostatectomy in metastatic prostate cancer: a review","volume":"35","author":"Metcalfe","year":"2017","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.002_bib50","first-page":"794","article-title":"Radical prostatectomy for patients with oligometastatic prostate cancer","volume":"31","author":"Ahmad","year":"2017","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.002_bib51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5152\/tud.2022.22064","article-title":"Oligometastatic prostate cancer: is there a role for surgery? A narrative review","volume":"48","author":"Martorana","year":"2022","journal-title":"Turk J Urol"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.002_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11934-023-01173-6","article-title":"Local therapeutics for the treatment of oligo metastatic prostate cancer","volume":"24","author":"Jalfon","year":"2023","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.002_bib53","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bju.15055","article-title":"The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer","volume":"125","author":"Ranasinghe","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.002_bib54","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MOU.0000000000001180","article-title":"Role of cytoreductive radical prostatectomy in men with oligometastatic prostate cancer on molecular imaging","volume":"34","author":"Robesti","year":"2024","journal-title":"Curr Opin Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.002_bib55","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/MOU.0000000000000445","article-title":"Radical prostatectomy in oligometastatic prostate cancer","volume":"27","author":"Mandel","year":"2017","journal-title":"Curr Opin Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.002_bib56","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41391-021-00335-2","article-title":"Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: a propensity score-based study","volume":"24","author":"Wang","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.ucl.2026.02.002_bib57","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jvir.2017.03.012","article-title":"Retrospective review of percutaneous image-guided ablation of oligometastatic prostate cancer: a single-institution experience","volume":"28","author":"Erie","year":"2017","journal-title":"J Vasc Intervent Radiol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:22:50Z","timestamp":1778718170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0094014326000029"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.002","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-Evaluating the Role of Locoregional Therapy in Metastatic Prostate Cancer: A Review of Current Evidence and Evolving Clinical Approaches","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}